Bactrim

CHARACTERISTICS OF THE MEDICINAL PRODUCT

1. NAME OF THE MEDICINAL PRODUCT

Bactrim, 400 mg + 80 mg, tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Sulfamethoxazole + Trimethoprim
Bactrim, 400 mg + 80 mg, tablets:
1 tablet contains: 400 mg of sulfamethoxazole and 80 mg of trimethoprim
The combination of sulfamethoxazole and trimethoprim in a mass ratio of 5:1 is known as co-trimoxazole.
A full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet
White or almost white, round, biconvex tablet with a diameter of about 11 mm with the inscription "BACTRIM" on one side and a dividing line on the other side.
The tablet can be divided into equal doses.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

The medicinal product Bactrim can be used after considering the benefit-risk ratio, reviewing epidemiological data and bacterial resistance.
Therapeutic indications are limited to infections caused by microorganisms sensitive to co-trimoxazole (see section 5).
When deciding to treat with Bactrim, official recommendations for the proper use of antibacterial agents should be taken into account.
Bactrim should be used to treat or prevent infections, only in cases where it has been confirmed or there is a justified suspicion that they were caused by bacteria or other microorganisms sensitive to co-trimoxazole. In the absence of such data, in the process of empirical selection of appropriate antibiotic therapy, local epidemiological conditions and antimicrobial susceptibility of microorganisms should be taken into account.
Bactrim is indicated for the treatment of adults and adolescents over 12 years of age.
Therapeutic Indications:

• respiratory tract infection - in case of exacerbation of chronic bronchitis;
• otitis media;
• gastrointestinal tract infection, including typhoid and traveler's diarrhea;
• treatment and prophylaxis (primary and secondary) of pneumonia caused by Pneumocystis jiroveciiin adults and adolescents, particularly in individuals with severe immune system disorders;

spcpl-pl-bactab-080-jul25-clean.docx
1

• urinary tract infection and soft chancre.

4.2 Posology and Method of Administration

Note: If it is necessary to administer two or more tablets at once to achieve the recommended dose, Bactrim Forte, 800 mg + 160 mg, tablets can be used.
For use in children under 12 years of age, Bactrim is mainly intended in the form of syrup (200 mg + 40 mg)/5 mL, syrup.
Dosage
Adults and adolescents over 12 years of age with normal renal function
2 tablets of Bactrim administered every 12 hours.
In case of severe infections, the dose can be increased to 3 tablets of Bactrim administered every 12 hours.
The minimum dose in case of long-term treatment (over 14 days) is 1 tablet of Bactrim administered every 12 hours.
In case of acute infections, Bactrim should be administered for at least 5 days or until the patient has not shown symptoms of infection for at least 2 days. If there is no clinical improvement after 7-day treatment, the patient's condition should be re-evaluated.
Pneumonia caused by Pneumocystis jirovecii
In treatment, a dose not exceeding 100 mg/kg/day of sulfamethoxazole and 20 mg/kg/day of trimethoprim should be used, in equal divided doses administered every 6 hours, for 14 days.
Table 1. Maximum doses of Bactrim depending on the body weight of patients with pneumonia caused by Pneumocystis jirovecii.
In prophylaxis of pneumonia caused by Pneumocystis jirovecii, the recommended dose in adults and adolescents is 2 tablets of Bactrim once a day. Results of a study conducted in HIV-infected patients also indicate the effectiveness of using 1 tablet of Bactrim once a day.
In children, in prophylaxis of pneumonia caused by Pneumocystis jirovecii, the recommended daily dose is 750 mg/m²/day of sulfamethoxazole and 150 mg/m²/day of trimethoprim, divided into two equal doses, for three consecutive days a week. The total daily dose should not exceed 1600 mg of sulfamethoxazole and 320 mg of trimethoprim.
Table 2. Doses of Bactrim 400 mg + 80 mg tablets recommended in children for prophylaxis of pneumonia caused by Pneumocystis jirovecii.
spcpl-pl-bactab-080-jul25-clean.docx
2

Treatment with a single dose in uncomplicated, acute urinary tract infections
4 to 6 tablets of Bactrim used at once, taken in the evening after dinner or before bedtime.
Treatment of soft chancre
2 tablets of Bactrim twice a day. If after 7 days there are no visible signs of improvement, it is recommended to consider administering the drug for another 7 days. However, it should be borne in mind that the lack of response to treatment may indicate that the disease is caused by resistant strains.
Dosage in patients with renal impairment
Recommended dosing regimen in patients with renal impairment:
Creatinine clearance > 30 mL/min: standard dosing.
Creatinine clearance 15 – 30 mL/min: half of the standard dose.
Creatinine clearance <15 ml min: bactrim is contraindicated (see section 4.3).
Dosage in patients undergoing dialysis
Patients undergoing hemodialysis should initially receive a normal loading dose of TMP-SMZ, and then an additional half dose after each hemodialysis.
Peritoneal dialysis results in minimal elimination of TMP and SMZ. It is not recommended to use TMP-SMZ in patients undergoing peritoneal dialysis.
Dosage in elderly patients
In elderly patients with normal renal function, the same doses as in adults should be used.
Method of administration
Oral administration. It is best to take the product after a meal with a sufficient amount of fluids.

4.3 Contraindications

Bactrim is absolutely contraindicated:

• in patients with hypersensitivity to the active substances or to any of the excipients listed in section 6.1;
• in patients with significant liver parenchymal damage;
• in patients with severe renal impairment with creatinine clearance <15 ml min (see section 4.2);< li>
• in combination with dofetilide (see section 4.5);
• in children under 6 weeks of age.

4.4 Special Warnings and Precautions for Use

In case of skin rash or other severe adverse reactions, the use of the drug should be discontinued immediately.
Particular caution should be exercised when using Bactrim in patients with a history of severe allergy or bronchial asthma.
There is an increased risk of severe adverse reactions:
spcpl-pl-bactab-080-jul25-clean.docx
3

• in elderly patients,
• in case of concomitant diseases, such as renal and/or hepatic impairment,
• in case of concomitant use of other drugs (the risk may depend on the dose and duration of treatment).

Severe Adverse Reactions
Rarely, fatal cases have been reported in association with adverse reactions such as blood disorders, severe skin reactions (SCAR) - such as severe bullous erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP)) and fulminant hepatic necrosis.

• During the use of Bactrim, life-threatening skin reactions have been reported: Stevens-Johnson syndrome and toxic epidermal necrolysis.
• Patients should be informed about the signs and symptoms and closely monitored for skin reactions. The greatest risk of Stevens-Johnson syndrome or toxic epidermal necrolysis occurs within the first few weeks of treatment.
• If signs or symptoms of Stevens-Johnson syndrome or toxic epidermal necrolysis occur (e.g., progressive skin rash often with blisters or mucosal lesions), treatment with Bactrim should be discontinued.
• The best results in cases of Stevens-Johnson syndrome and toxic epidermal necrolysis are obtained with early diagnosis and immediate discontinuation of the suspected product. Early discontinuation of the product is associated with a better prognosis.
• If a patient has developed Stevens-Johnson syndrome or toxic epidermal necrolysis while using Bactrim, Bactrim should not be used again in this patient.

In order to minimize the risk of adverse reactions, treatment with Bactrim should be as short as possible, especially in elderly patients.
Hypersensitivity Reactions and Allergic Reactions
Pulmonary infiltrates observed in association with eosinophilic or allergic pneumonitis may manifest as cough and shortness of breath. If these symptoms occur or worsen, the patient should be re-evaluated and consideration should be given to discontinuing treatment with Bactrim.
Respiratory Toxicity
During treatment with co-trimoxazole, very rare cases of severe respiratory toxicity have been reported, sometimes transforming into acute respiratory distress syndrome (ARDS). The first symptoms of ARDS may be such pulmonary symptoms as cough, fever, and shortness of breath, with concurrent radiological signs indicating pulmonary infiltrates and impaired lung function. In such circumstances, treatment with co-trimoxazole should be discontinued and appropriate therapy should be administered.
Renal Effects
Sulfonamides, including Bactrim, may cause increased diuresis, especially in patients with heart failure.
It is recommended to closely monitor serum potassium levels and renal function in patients taking high doses of Bactrim, used in patients with pneumonia caused by Pneumocystis jirovecii, or in patients taking standard doses of Bactrim, who have potassium metabolism disorders or renal impairment or who are taking drugs that cause hyperkalemia (see section 4.5).
Special Patient Populations
In case of renal impairment, the dose should be adjusted accordingly (see section 4.2). Patients with severe renal impairment (i.e., creatinine clearance 15-30 mL/min) taking TMP-SMZ should be closely monitored for signs and symptoms of toxicity, such as nausea, vomiting, and hyperkalemia.
Long-term Treatment
Regular blood tests should be performed in patients undergoing prolonged treatment with Bactrim. In case of a significant decrease in any blood element, administration of Bactrim should be discontinued.
Except in exceptional cases, it is not recommended to use Bactrim in patients with severe hematological disorders.
Cases of pancytopenia have been reported in patients taking co-trimoxazole (see sections 4.3 and

• 4.5).

Hematological adverse reactions associated with folate deficiency may occur in elderly patients, in patients with pre-existing folate deficiency, or in patients with renal impairment. These reactions are reversible after administration of folinic acid.
Hemophagocytic Lymphohistiocytosis
Very rarely, cases of hemophagocytic lymphohistiocytosis (HLH) have been reported in patients treated with co-trimoxazole. This is a life-threatening disorder of abnormal immune activation, characterized by clinical signs and symptoms such as severe systemic inflammation (e.g., fever, hepatosplenomegaly, hypertriglyceridemia, hypofibrinogenemia, high serum ferritin levels, cytopenia, and hemophagocytosis). Patients with early signs of abnormal immune activation should be diagnosed promptly. If HLH is diagnosed, treatment with co-trimoxazole should be discontinued.
During long-term treatment with Bactrim (especially in patients with renal impairment), regular urine tests and renal function tests should be performed. During treatment, adequate fluid intake and diuresis should be ensured to prevent crystalluria.
Due to the risk of hemolysis, Bactrim should not be used in patients with G6PD deficiency, except in cases of absolute necessity. In such cases, only minimal doses of the drug should be administered.
As with other sulfonamide-containing drugs, caution is recommended when treating patients with porphyria and thyroid dysfunction.
Patients belonging to the "slow acetylators" group may have a greater tendency to individual hypersensitivity to sulfonamides (idiosyncrasy).

Bactrim contains sodium

The medicinal product contains less than 1 mmol (23 mg) of sodium per tablet, which means that the medicinal product is considered "sodium-free".

4.5 Interaction with Other Medicinal Products and Other Forms of Interaction

Pharmacokinetic Interactions

spcpl-pl-bactab-080-jul25-clean.docx
5
Drugs transported by OCT2
Trimethoprim is an inhibitor of the organic cation transporter 2 (OCT2) and a weak inhibitor of CYP2C8. Sulfamethoxazole is a weak inhibitor of CYP2C9.
Systemic exposure to drugs transported by OCT2 may increase when co-administered with TMP-SMZ. Examples include dofetilide, amantadine, memantine, and lamivudine.
Dofetilide
TMP-SMZ should not be administered in combination with dofetilide (see section 4.3).
It has been shown that trimethoprim inhibits the renal excretion of dofetilide. The combination of trimethoprim (160 mg) with sulfamethoxazole (800 mg) administered twice a day with dofetilide in a dose of 500 μg administered twice a day for 4 days resulted in an increase in the area under the curve (AUC) of dofetilide by 103% and an increase in the maximum concentration (C) by 93%. Dofetilide may cause severe ventricular arrhythmias associated with QT interval prolongation, including torsades de pointes, which are directly related to the dofetilide concentration in the blood.
Amantadine and Memantine
Patients taking amantadine or memantine may be at increased risk of adverse neurological events, such as delirium and myoclonus.
Drugs metabolized mainly by CYP2C8
Systemic exposure to drugs metabolized mainly by CYP2C8 may increase when co-administered with TMP-SMZ. Examples include paclitaxel, amiodarone, dapsone, repaglinide, rosiglitazone, and pioglitazone.
Paclitaxel and amiodarone have a narrow therapeutic index. Therefore, it is not recommended to use them in combination with TMP-SMZ.
Dapsone
Both dapsone and TMP-SMZ may cause methemoglobinemia, which may lead to pharmacokinetic and pharmacodynamic interactions. Patients taking dapsone and TMP-SMZ should be monitored for methemoglobinemia. If possible, alternative therapies should be considered.
Repaglinide, Rosiglitazone, Pioglitazone
Patients taking repaglinide, rosiglitazone, or pioglitazone should be regularly monitored for hypoglycemia.
Drugs metabolized mainly by CYP2C9
Systemic exposure to drugs metabolized mainly by CYP2C9 may increase when co-administered with TMP-SMZ. Examples include coumarins (warfarin, acenocoumarol, phenprocoumon), phenytoin, and sulfonylurea derivatives (glibenclamide, gliclazide, glipizide, chlorpropamide, and tolbutamide).
Coumarins
In patients taking coumarins, coagulation should be monitored.
Phenytoin
A 39% increase in the half-life and a 27% decrease in the clearance of phenytoin have been observed after administration of TMP-SMZ in standard doses. Patients taking phenytoin should be monitored for signs of phenytoin toxicity.
Sulfonylurea derivatives
Patients taking sulfonylurea derivatives (including glibenclamide, gliclazide, glipizide, chlorpropamide, and tolbutamide) should be regularly monitored for hypoglycemia.
Digoxin
An increase in digoxin levels in the blood may occur during concomitant use of TMP-SMZ, especially in elderly patients. Digoxin levels in the blood should be monitored.

Pharmacodynamic Interactions and Interactions with an Undefined Mechanism

The frequency and severity of myelotoxic and nephrotoxic adverse reactions may increase if TMP-SMZ is administered concomitantly with other drugs with proven myelosuppressive or nephrotoxic effects, such as nucleoside analogs, tacrolimus, azathioprine, or mercaptopurine. Patients taking TMP-SMZ concomitantly with these drugs should be monitored for signs of myelo- and/or nephrotoxicity.
Clozapine
Concomitant use with clozapine, a drug that may cause agranulocytosis, should be avoided.
Diuretics
An increased incidence of thrombocytopenia has been observed in elderly patients taking certain diuretics, especially thiazides. In patients taking diuretics, platelet count should be regularly monitored.
Methotrexate
Sulfonamides, including sulfamethoxazole, may compete with protein binding and renal transport of methotrexate, thereby increasing the fraction of free methotrexate and its overall effect on the body.
Cases of pancytopenia have been reported in patients taking trimethoprim and methotrexate concomitantly (see section 4.4). Trimethoprim has a low affinity for human dihydrofolate reductase, but may increase the toxicity of methotrexate, especially if there are risk factors such as advanced age, hypoalbuminemia, impaired renal function, decreased bone marrow reserve, and high doses of methotrexate. Patients at risk should be treated with folic acid or folinic acid to counteract the adverse effect of methotrexate on hematopoiesis.
Pyrimethamine
Isolated cases of megaloblastic anemia have been reported in patients taking pyrimethamine for malaria prophylaxis in doses exceeding 25 mg per week and concomitantly taking TMP-SMZ.
Potassium-sparing drugs (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers)
Due to the potassium-sparing effect of TMP-SMZ, caution should be exercised when TMP-SMZ is administered concomitantly with other drugs that increase potassium levels in the blood, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and prednisolone.
Cyclosporine
A transient deterioration in renal function has been observed in patients treated with TMP-SMZ and cyclosporine after kidney transplantation.
spcpl-pl-bactab-080-jul25-clean.docx
7
Oral hypoglycemic agents
Rarely, severe hypoglycemia may occur. The patient should be warned and advised to monitor blood glucose levels more frequently. It may be necessary to adjust the dose of oral hypoglycemic agents during and after treatment with Bactrim.
Effect on Diagnostic Tests
TMP-SMZ, especially trimethoprim, may interfere with the measurement of methotrexate levels in the blood using a competitive binding technique with bacterial dihydrofolate reductase as the binding protein. However, there is no interference when methotrexate levels are measured by radioimmunoassay.
The presence of TMP and SMZ may affect the measurement of creatinine levels in the blood, performed using the Jaffe reaction with alkaline picrate. This may result in an overestimation of the creatinine level in the blood by about 10%.

4.6 Fertility, Pregnancy, and Lactation

Pregnancy
There is no conclusive evidence of the risk of fetal malformations in women treated with co-trimoxazole in early pregnancy. The results of two large observational studies indicate an increased risk of spontaneous abortion (2 to 3.5 times) in women who used trimethoprim in monotherapy or in combination with sulfamethoxazole in the first trimester of pregnancy compared to women who did not use antibiotics or used penicillins. Animal studies have shown that very high doses of co-trimoxazole cause fetal malformations typical of folate antagonists.
Since both trimethoprim and sulfamethoxazole cross the placental barrier and may affect folate metabolism, the use of Bactrim in pregnancy can be considered only when the expected benefits of treatment outweigh the potential risk to the fetus.
In such cases, pregnant women or women planning to become pregnant during treatment with Bactrim should be advised to take folic acid in a dose of 5 mg per day. Whenever possible, the use of Bactrim should be avoided in the last trimester of pregnancy due to the risk of kernicterus in the newborn (see section 5.2).
Breastfeeding
Both trimethoprim and sulfamethoxazole pass into human milk.
Although the amount of the drug ingested by the child of a mother treated with co-trimoxazole is small, the risk to the child (kernicterus, hypersensitivity) should be weighed against the expected therapeutic benefits for the mother (see section 5.2).
Fertility
There are no available data on the effect on fertility.

4.7 Effects on Ability to Drive and Use Machines

There are no data available.

4.8 Undesirable Effects

In recommended doses, Bactrim is generally well tolerated. The most common adverse reactions are skin rashes and gastrointestinal disorders.
The following criteria have been used to determine the frequency of adverse reactions:
very common ≥ 1/10, common ≥ 1/100 and <1>

spcpl-pl-bactab-080-jul25-clean.docx
9

spcpl-pl-bactab-080-jul25-clean.docx
10

4.9 Overdose

Symptoms
Among the symptoms of acuteoverdose, nausea, vomiting, diarrhea, headache, dizziness, mental and visual disturbances may occur; in severe cases, crystalluria, hematuria, and anuria may occur.
In the case of chronicoverdose, bone marrow suppression may occur, manifested by thrombocytopenia or leukopenia, as well as other blood count abnormalities resulting from folic acid deficiency.
Treatment
Depending on the symptoms, measures should be taken to prevent further absorption of the drug, increase renal excretion by using forced diuresis (alkalization of urine increases the excretion of sulfamethoxazole), hemodialysis should be used (note! peritoneal dialysis is not effective), blood count and electrolyte levels should be monitored. In case of jaundice or significant blood count abnormalities, appropriate treatment should be used. It may be indicated to administer 3-6 mg of calcium folinate intramuscularly for 5-7 days to counteract the effect of trimethoprim on hemopoiesis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: systemic anti-infective agents with bactericidal properties, sulfonamides with trimethoprim,
ATC code: J 01 EE 01
Mechanism of action
Bactrim contains co-trimoxazole: two active substances - sulfamethoxazole and trimethoprim - acting synergistically by sequentially blocking two bacterial enzymes that catalyze consecutive stages of folic acid biosynthesis in microorganisms.
Usually, this results in a bactericidal effect in vitroat concentrations at which individual substances act only bacteriostatically. Additionally, co-trimoxazole often acts effectively on bacteria resistant to one of the two substances that make it up.
Co-trimoxazole has been shown to have antibacterial activity in vitroagainst a wide range of Gram-positive and Gram-negative pathogenic strains, although their susceptibility may depend on the geographical region.
Microorganisms usually susceptible (MIC <80 mg l)*< p>

• cocci: Moraxella catarrhalis
• Gram-negative rods: Haemophilus influenzae(β-lactamase-positive, β-lactamase-negative), Haemophilus parainfluenzae, Escherichia coli, Citrobacter freundii, other Citrobacterspp., Klebsiella pneumoniae, Klebsiella oxytoca, other Klebsiellaspp., Enterobacter cloacae, Enterobacter aerogenes, Hafnia alvei, Serratia marcescens, Serratia liquefaciens, other Serratiaspp., Proteus mirabilis,Proteus vulgaris, Morganella morganii, Shigellaspp., Yersiniaenterocolitica,other Yersiniaspp., Vibrio choleraespcpl-pl-bactab-080-jul25-clean.docx 13
• various Gram-negative rods: Edwardsiella tarda, Alcaligenes faecalis, Pseudomonas cepacia,Burkholderia (Pseudomonas) pseudomallei

Based on clinical experience, the following microorganisms are considered susceptible: Brucella,
Listeria monocytogenes, Nocardia asteroides, Pneumocystis jirovecii, Cyclospora cayetanensis.
Partially susceptible microorganisms (MIC = 80-160 mg/l)*

• cocci: Staphylococcus aureus(methicillin-susceptible and methicillin-resistant), Staphylococcusspp .(coagulase-negative), Streptococcus pneumoniae(penicillin-susceptible, penicillin-resistant)
• Gram-negative rods: Haemophilus ducreyi, Providencia rettgeri,other Providenciaspp., Salmonella typhi, Salmonella enteritidis, Stenotrophomonas maltophilia(formerly Xanthomonasmaltophilia)
• various Gram-negative rods: Acinetobacter lwoffi, Acinetobacter anitratus(mainly A. baumannii), Aeromonas hydrophila

Resistant microorganisms (MIC >160 mg/l)*

• Mycoplasmaspp., Mycobacterium tuberculosis, Treponema pallium

* sulfamethoxazole equivalent
If empirical treatment with co-trimoxazole is initiated, it should be determined whether the bacterial strains that are generally susceptible to it do not show resistance to the drug in a given area.
In order to rule out resistance, especially in the case of infections that may be caused by partially susceptible pathogens, the isolated microorganisms should be tested for susceptibility.
Susceptibility to co-trimoxazole can be determined using standardized methods, such as the diffusion-plate method and the dilution method, recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The EUCAST-recommended susceptibility criteria are listed in the table below.
Table 3.
EUCAST-recommended susceptibility criteria (European Committee on Antimicrobial Susceptibility Testing)
Diffusion-plate method ,
Zone of inhibition diameter (mm)
Dilution method ,
MIC (μg/mL)
TMP
Enterobacteriaceae
Susceptible
≥ 16
≤ 2
Resistant
<13
> 4
Acinetobacterspp.
Susceptible
≥ 16
≤ 2
Resistant
<13
> 4
Stenotrophomonas maltophilia
Susceptible
≥ 16
≤ 4
Resistant
<16
> 4
Staphylococcusspp.
Susceptible
≥ 17
≤ 2
Resistant
<14
> 4
Enterococcusspp.
Susceptible
≥ 50
≤ 0.03
Resistant
<21
> 1
Streptococcus pneumoniae
Susceptible
≥ 18
≤ 1
Resistant
<15
> 2
spcpl-pl-bactab-080-jul25-clean.docx
14

Disk: 1.25 μg trimethoprim and 23.75 μg sulfamethoxazole
trimethoprim and sulfamethoxazole in a ratio of 1 to 19
The limit values are based on data from therapy using high doses, ≥ 240 mg trimethoprim and 1.2 g sulfamethoxazole administered together twice a day
The effectiveness of TMP and TMP-SMZ against enterococci is uncertain, so the "wild" (wild-type) strain is classified as moderately susceptible (MS).
There are no EUCAST limit values for the following species with defined values according to the Clinical and Laboratory Standards Institute (CLSI) (disk [mm]; dilution [µg / mL]) given in parentheses:

• CLSI) (disk [mm]; dilution [µg / mL]) given in parentheses:
• Burkholderia cepacia(S, ≥16; MS, 11-15; R, ≤10; and S, ≤2/≤38; MS, not available; R, ≥4/≥76)
• Other species not belonging to the Enterobacteriaceaefamily, i.e. Pseudomonasspp. and other non-fermenting, glucose-negative rods, but excluding Pseudomonasaeruginosa, Acinetobacterspp., Burkholderia cepaciaand Stenotrophomonas maltophila(disk, not available; and S, ≤2/≤38; MS, not available; R, ≥4/≥76)
• Neisseria meningitidis(S, ≥30; MS, 26-29; R, ≤25; and S, ≤0.12/≤2.4; MS, 0.25/4.75; R, ≥0.5/≥9.5)

5.2 Pharmacokinetic properties

Absorption
After oral administration, sulfamethoxazole and trimethoprim are rapidly and completely (90%) absorbed in the upper gastrointestinal tract, and the maximum concentration is reached 2-4 hours after administration.
After oral administration of a single dose of 800 mg sulfamethoxazole and 160 mg trimethoprim, the maximum concentration in serum reaches a value of 40 to 80 µg/mL for sulfamethoxazole and 1.5 to 3 µg/mL for trimethoprim within 1-4 hours. After repeated administration of the above doses at 12-hour intervals, the minimum serum concentration at steady state, reached after 2-3 days, is 1.3 to 2.8 µg/mL for trimethoprim and 32 to 63 µg/mL for sulfamethoxazole.
Bioavailability
The absorption of TMP (trimethoprim) and SMZ (sulfamethoxazole) is complete, which reflects the absolute bioavailability after oral administration, reaching 100% for both drugs.
Distribution
The volume of distribution is approximately 1.6 l/kg for TMP and approximately 0.2 l/kg for SMZ, while protein binding in serum is 37% for TMP and 62% for SMZ.
spcpl-pl-bactab-080-jul25-clean.docx
15
It has been shown that trimethoprim penetrates more easily than sulfamethoxazole into unchanged inflamed prostate tissue, seminal fluid, vaginal discharge, saliva, normal and inflamed lung tissue, and bile. In the case of cerebrospinal fluid and aqueous humor, penetration is similar for both substances.
A significant amount of trimethoprim and a smaller amount of sulfamethoxazole penetrate from the bloodstream into the interstitial fluid and other extravascular fluids in the body. The concentration of sulfamethoxazole and trimethoprim is higher than the minimum inhibitory concentration in the case of most susceptible microorganisms.
In humans, trimethoprim and sulfamethoxazole have been detected in fetal tissues (placenta, liver, lungs), in umbilical cord blood, and in amniotic fluid, indicating that both drugs cross the placenta. In general, the concentration of trimethoprim in the fetus is similar, and that of sulfamethoxazole is lower than in the mother (see section 4.6).
Both components of co-trimoxazole are excreted into human milk. The concentrations in human milk are similar for trimethoprim and lower for sulfamethoxazole compared to the concentration in blood serum (see section 4.6).
Metabolism
About 30% of the TMP dose is metabolized. Based on the results of an in vitrostudy using human liver microsomes, the participation of CYP3A4, CYP1A2, and CYP2C9 in the oxidative metabolism of TMP cannot be excluded. The main metabolites of trimethoprim are 1- and 3-oxides and 3- and 4-hydroxides. Some of these metabolites are microbiologically active.
About 80% of the SMZ dose is metabolized in the liver, mainly to N-acetyl derivative (≈ 40% of the dose) and to a lesser extent by conjugation with glucuronic acid. SMZ also undergoes oxidative metabolism. The first stage of the oxidative pathway, which leads to the formation of a hydroxylamine derivative, is catalyzed by CYP2C9.
Elimination
The half-lives of both substances are similar (averaging 10 hours for trimethoprim and averaging 11 hours for sulfamethoxazole).
The half-lives do not change significantly in elderly patients.
Both substances, as well as their metabolites, are almost completely excreted by the kidneys as a result of glomerular filtration and tubular secretion, causing the concentration of both active substances in urine to be much higher than in blood. About two-thirds of the TMP dose and one-fifth of the SMZ dose are excreted in the urine in an unchanged form. The total clearance of TMP in serum is 1.9 mL/min/kg. The total clearance of SMZ in serum is 0.32 mL/min/kg. A small amount of each substance is excreted in the feces.
In patients with severe renal impairment (creatinine clearance 15-30 mL/min), the half-life of trimethoprim and sulfamethoxazole in the elimination phase is prolonged, which requires adjustment of the dosing regimen. Intermittent or continuous ambulatory peritoneal dialysis does not significantly affect the elimination of TMP-SMZ (trimethoprim-sulfamethoxazole). TMP and SMZ are removed to a significant extent during hemodialysis and hemofiltration. It is recommended to increase the dose of TMP-SMZ by 50% after each hemodialysis session. In children with renal impairment (CLcr <30 ml min), the clearance of tmp is reduced, and half-life elimination prolonged. dosing tmp-smz in pediatric patients with renal impairment should depend on function (see section 4.2).
Renal impairment
In patients with severe renal impairment (creatinine clearance 15-30 mL/min), the half-life of both components is prolonged, which requires adjustment of the dosing regimen. Intermittent or continuous ambulatory peritoneal dialysis does not significantly affect the elimination of TMP-SMZ (trimethoprim-sulfamethoxazole). TMP and SMZ are removed to a significant extent during hemodialysis and hemofiltration. It is suggested to increase the dose of TMP-SMZ by 50% after each hemodialysis session. In children with renal impairment (CLcr <30 ml min), the clearance of tmp is reduced, and half-life elimination prolonged. dosing tmp-smz in pediatric patients with renal impairment should depend on function (see section 4.2).
Hepatic impairment
The pharmacokinetics of TMP and SMZ in patients with moderate or severe hepatic impairment does not differ significantly from that observed in healthy individuals.
Patients with cystic fibrosis
In patients with cystic fibrosis, the renal clearance of TMP and the metabolic clearance of SMZ are increased. As a result, the total clearance in serum is increased, and the half-life of elimination is shortened for both drugs.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Povidone K 30
Croscarmellose sodium
Magnesium stearate
Sodium lauryl sulfate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

spcpl-pl-bactab-080-jul25-clean.docx
17
5 years.

6.4 Special precautions for storage

No special storage precautions for the medicinal product.

6.5 Nature and contents of container

20 pieces - 2 blisters of 10 tablets each.
Blister pack of aluminum/PVC foil in a cardboard box.

6.6 Special precautions for disposal and preparation of the medicinal product for administration

administration
No special requirements. Any unused medicinal product or waste materials should be disposed of in accordance with local regulations.

7. MARKETING AUTHORIZATION HOLDER

RESPONSIBLE FOR BATCH RELEASE

EUMEDICA Pharmaceuticals GmbH
Basler Straße 126
DE-79540 Lörrach
Germany
e-mail: info@eumedicapharmaceuticals.de

8. MARKETING AUTHORIZATION NUMBER

Marketing Authorization Number: R/2762

9. DATE OF FIRST MARKETING AUTHORIZATION AND DATE OF LAST RENEWAL

OF MARKETING AUTHORIZATION

Date of first marketing authorization: 8.07.1994
Date of last renewal of marketing authorization: 21.02.2014

10. DATE OF REVISION OF THE SUMMARY OF PRODUCT CHARACTERISTICS

07/2025

spcpl-pl-bactab-080-jul25-clean.docx
18